Key result
Body mass up to 190 kg did not significantly alter peak or trough anti-Xa levels in patients receiving weight-based dalteparin for venous thromboembolism (p > 0.2).
Why the study?
Does body weight influence the anticoagulant response to weight-based dosing of dalteparin in patients with venous thromboembolism?
Population
37 patients with deep vein thrombosis or pulmonary embolism and serum creatinine < 150 micromol/l…
Design
Cohort
Follow-up
5 days
Authors
Loading...
Supports weight-based dalteparin dosing without cap in obese VTE patients; leaves open need for larger prospective confirmation.
Cohort (n=37)
Does body weight influence the anticoagulant response to weight-based dosing of dalteparin in patients with venous thromboembolism?
p-value: p=> 0.2
Weight-based dosing of dalteparin using actual body weight provides a consistent anticoagulant response without the need for dose capping in obese patients up to 190 kg with normal or near-normal renal function.
Wilson et al. (2001) conducted a cohort in Venous thromboembolism (n=37). Weight-based dalteparin dosing vs. Compared across three weight classes (within 20% IBW, 20-40% IBW, >40% IBW) was evaluated on Peak and trough anti-Xa levels (p=> 0.2). Body mass up to 190 kg did not significantly alter peak or trough anti-Xa levels in patients receiving weight-based dalteparin for venous thromboembolism (p > 0.2).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: